Abeona Therapeutics Inc. (ABEO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 10 | 3 | 1 | 4 | 0 | 6 | - | - |
| Operating profit | $m | -89 | - | ||||||
| Net profit | $m | -84 | -85 | -40 | -54 | -64 | 71 | - | -48 |
| EPS reported | $ | 1.01 | - | ||||||
| Operating cashflow per share | $ | -1.44 | - | ||||||
| Capex per share | $ | 0.15 | - | ||||||
| FCF per share | $ | -1.59 | - | ||||||
| Free cash flow | $m | -84 | - | ||||||
| Net debt | $m | -171 | - | ||||||
| Book value equity | $m | 159 | - | ||||||
| Book value per share | $ | 2.41 | - | ||||||
| Number of shares | m | 66.14 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 5.22 | - | ||||||
| P/B LTM | x | 1.75 | - | ||||||
| P/S LTM | x | 47.95 | - | ||||||
| P/FCF LTM | x | -3.31 | - | ||||||
| EV/EBITDA LTM | x | 2.87 | - | ||||||
| EV/Sales LTM | x | 38.76 | - | ||||||
| Earnings Yield LTM | % | +19.16% | - | ||||||
| FCF Yield | % | -30.21% | - | ||||||
| Quality | |||||||||
| ROE | % | +44.71% | - | ||||||
| ROIC | % | -43.98% | - | ||||||
| Operating margin | % | -15.37% | - | ||||||
| Gross margin | % | +73.68% | - | ||||||
| FCF/Sales | % | -1448.5% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -3.38 | - | ||||||
| Net Debt/EBITDA | x | -0.68 | - | ||||||
| EBIT/Net interest | x | -23.92 | - | ||||||
| Net debt/market cap | % | +7.18% | - | ||||||
| Net debt/Equity | x | -1.08 | - | ||||||
| Gross debt/equity | x | 0.16 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free